NCT07217704 2026-04-20
FAPI-GO
SOFIE
Phase 3 Recruiting
Clinical Trials
76 trialsNCT03653507 2026-04-17
GLOW
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT05152147 2026-04-17
HERIZON-GEA-01
Jazz Pharmaceuticals
Phase 3 Active not recruiting
NCT07431281 2026-04-13
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT07518147 2026-04-08
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 3 Not yet recruiting
NCT05568095 2026-04-02
STAR-221
Arcus Biosciences, Inc.
Phase 3 Active not recruiting
NCT06731478 2026-03-16
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo
Phase 3 Recruiting
NCT03221426 2026-03-09
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06346392 2026-03-09
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
Phase 3 Recruiting
NCT04882241 2026-03-06
KEYNOTE-585
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03675737 2026-02-27
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT06532006 2026-02-27
A Phase â…¢ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Recruiting
NCT05052801 2026-02-19
FORTITUDE-101
Amgen
Phase 3 Active not recruiting
NCT03504397 2026-02-13
Spotlight
Astellas Pharma Inc
Phase 3 Active not recruiting
NCT07315750 2026-01-21
A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
RemeGen Co., Ltd.
Phase 3 Recruiting
NCT04342910 2026-01-20
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Recruiting
NCT04704934 2026-01-12
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Daiichi Sankyo
Phase 3 Active not recruiting
NCT06093425 2025-12-17
Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 3 Not yet recruiting
NCT05111626 2025-12-15
FORTITUDE-102
Amgen
Phase 3 Active not recruiting
NCT03615326 2025-12-11
MK-3475-811
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03813784 2025-09-16
A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Completed
NCT02872116 2025-08-07
CheckMate649
Bristol-Myers Squibb
Phase 3 Completed
NCT06944496 2025-04-25
A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
RemeGen Co., Ltd.
Phase 3 Not yet recruiting
NCT06296706 2024-11-14
A Clinical Study of Docetaxel for Injection (Albumin-bound) in Patients With Gastric Cancer
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Recruiting
NCT00400179 2024-09-19
A Safety and Efficacy Study in Patients With Gastric Cancer
Taiho Oncology, Inc.
Phase 3 Completed
NCT01285557 2024-09-19
DIGEST
Taiho Oncology, Inc.
Phase 3 Terminated
NCT05144854 2024-09-05
A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Ono Pharmaceutical Co., Ltd.
Phase 3 Active not recruiting
NCT02500043 2024-09-03
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc.
Phase 3 Completed
NCT01839773 2024-07-25
DREAM
Daehwa Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT02267343 2024-05-03
Study of ONO-4538 in Unresectable Advanced or Recurrent Gastric Cancer
Ono Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT03006705 2024-05-03
Study of Adjuvant ONO-4538 With Resected Gastric Cancer
Ono Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT01924533 2024-03-22
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
AstraZeneca
Phase 3 Completed
NCT06177041 2024-02-28
M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase 3 Recruiting
NCT04714190 2023-12-21
A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression
RemeGen Co., Ltd.
Phase 3 Unknown
NCT01515748 2023-12-13
PRODIGY
Sanofi
Phase 3 Completed
NCT02178956 2023-11-15
BRIGHTER
Sumitomo Pharma America, Inc.
Phase 3 Completed
NCT02494583 2023-04-13
MK-3475-062
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03019588 2023-03-30
MK-3475-063
Merck Sharp & Dohme LLC
Phase 3 Terminated
NCT03745170 2023-03-01
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
NCT04222114 2023-01-31
Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis
LintonPharm Co.,Ltd.
Phase 3 Unknown
NCT03042611 2022-07-08
ANGEL
Elevar Therapeutics
Phase 3 Completed
NCT02370498 2022-06-06
MK-3475-061
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04139135 2022-06-06
A Clinical Study of HLX10 Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Neoadjuvant/Adjuvant Treatment of Gastric Cancer
Shanghai Henlius Biotech
Phase 3 Unknown
NCT02322593 2021-12-20
SOLAR
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT04486651 2021-01-28
HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer
Taizhou Hanzhong biomedical co. LTD
Phase 3 Unknown
NCT01774786 2020-12-30
JACOB
Hoffmann-La Roche
Phase 3 Completed
NCT02625623 2020-11-24
Avelumab in Third-Line Gastric Cancer (JAVELIN Gastric 300)
EMD Serono
Phase 3 Completed
NCT02545504 2020-05-26
GAMMA-1
Gilead Sciences
Phase 3 Completed
NCT00917384 2019-09-25
Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Eli Lilly and Company
Phase 3 Completed